rofecoxib has been researched along with Abdominal Pain in 5 studies
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 9.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 8.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 5.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 4.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| " This effect was prevented by rofecoxib treatment indicating the sensitivity of the model for pelvic pain related to peritonitis." | 3.80 | Use of dynamic weight bearing as a novel end-point for the assessment of abdominal pain in the LPS-induced peritonitis model in the rat. ( Gruen, M; Laux-Biehlmann, A; Nagel, J; Zollner, TM, 2014) |
| "Rofecoxib is a selective cyclooxygenase-2 inhibitor that has been approved for the treatment of osteoarthritis and management of acute pain." | 1.33 | Ischemic colitis associated with rofecoxib. ( Feltri, M; Meucci, G; Minoli, G; Radaelli, F; Spinzi, G; Terruzzi, V, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruen, M | 1 |
| Laux-Biehlmann, A | 1 |
| Zollner, TM | 1 |
| Nagel, J | 1 |
| Charachon, A | 1 |
| Petit, T | 1 |
| Lamarque, D | 1 |
| Soulé, JC | 1 |
| Radaelli, F | 1 |
| Feltri, M | 1 |
| Meucci, G | 1 |
| Spinzi, G | 1 |
| Terruzzi, V | 1 |
| Minoli, G | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Acevedo, E | 1 |
| Castañeda, O | 1 |
| Ugaz, M | 1 |
| Beaulieu, AD | 1 |
| Pons-Estel, B | 1 |
| Caeiro, F | 1 |
| Casas, N | 1 |
| Garza-Elizondo, M | 1 |
| Irazoque, F | 1 |
| Hinojosa, W | 1 |
| Gutierrez-Ureña, S | 1 |
| Vandormael, K | 1 |
| Rodgers, DB | 1 |
| Laurenzi, M | 1 |
1 review available for rofecoxib and Abdominal Pain
| Article | Year |
|---|---|
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Tr | 2000 |
1 trial available for rofecoxib and Abdominal Pain
| Article | Year |
|---|---|
Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygen | 2001 |
3 other studies available for rofecoxib and Abdominal Pain
| Article | Year |
|---|---|
Use of dynamic weight bearing as a novel end-point for the assessment of abdominal pain in the LPS-induced peritonitis model in the rat.
Topics: Abdominal Pain; Analysis of Variance; Animals; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Mo | 2014 |
[Acute ulcerative colitis in a patient treated with rofecoxib who took aspirin as self-medication].
Topics: Abdominal Pain; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Biopsy; | 2003 |
Ischemic colitis associated with rofecoxib.
Topics: Abdominal Pain; Colitis, Ischemic; Colon; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorr | 2005 |